

## Naturally Occurring T-Cell Response against Mutated p21 Ras Oncoprotein in Pancreatic Cancer

Boris Kubuschok,<sup>1</sup> Frank Neumann,<sup>1</sup> Rainer Breit,<sup>1</sup> Martina Sester,<sup>2</sup> Claudia Schormann,<sup>1</sup> Claudia Wagner,<sup>1</sup> Urban Sester,<sup>2</sup> Frank Hartmann,<sup>1</sup> Mathias Wagner,<sup>4</sup> Klaus Remberger,<sup>4</sup> Martin Schilling,<sup>3</sup> and Michael Pfreundschuh<sup>1</sup>

**Abstract** Mutated p21 ras proteins (muRas) are present in ~90% of pancreatic adenocarcinomas and express mutants which can function as cancer-specific antigens. To evaluate the frequency and magnitude of the natural T-cell response against muRas in 19 HLA-A2-positive patients with muRas-positive pancreatic carcinomas, antigen-experienced T lymphocytes in fresh peripheral blood mononuclear cells were shown by IFN- $\gamma$  enzyme-linked immunospot using muRas peptides (5-21) that encompass both HLA class I (HLA-A2)– and class II–restricted (HLA-DRB1) epitopes. Six of 19 patients (32%) were found to have a specific T-cell response against individual mutation-specific ras<sub>5-21</sub> but not against other ras mutations or wild-type ras. In contrast, none of 19 healthy subjects had T cells specifically secreting IFN- $\gamma$  ( $P = 0.004$ ). The T-cell response consisted of both CD8<sup>+</sup> and CD4<sup>+</sup> T cells but was dominated by CD8 T cells in three of four patients. MuRas<sub>5-14</sub> and muRas<sub>6-14</sub> were shown to specifically induce CD8<sup>+</sup> T-cell mediated cytotoxicity against HLA-A2-positive, muRas-bearing pancreatic carcinoma cells. The T-cell response was not correlated with prognostic or clinical variables such as tumor-node-metastasis status, stage, or survival. In conclusion, a natural T-cell response against muRas proteins that could be exploited for immunostimulatory therapeutic approaches has been shown in a significant proportion of patients with pancreatic cancer.

The *ras* proto-oncogenes (*H-ras*, *K-ras*, and *N-ras*) encode 21-kDa proteins with intrinsic GTPase activity that are involved in cell proliferation and differentiation. Point mutations in the *ras* proto-oncogenes have been identified in a wide range of human solid tumors, in particular carcinomas of the pancreas, colon, lung, and thyroid as well as myeloid malignancies. The majority of point mutations of the *ras* gene reside at codons 12, 13, and 61 (1). These mutations result in the production of aberrant proteins, which are structurally and functionally distinct from normal endogenous *ras* and, due to their strict tumor specificity, can function as targets for cellular and humoral immune responses in cancer patients (1–5) and healthy donors (6–8).

In pancreatic adenocarcinomas where *ras* point mutations occur in 80% to 90% of cases, it is the *K-ras* gene at codon 12 that is found frequently mutated. Replacement of the normal glycine (Gly) residue by an aspartic acid (Asp), valine (Val), cysteine (Cys), or arginine (Arg) residue accounts for ~98% of

all *ras* mutations in pancreatic carcinomas, rendering pancreatic cancer an ideal model for the investigations of T-cell responses against *ras* mutations at position 12. Previous studies have shown that CD4<sup>+</sup> T-cell immunity to position 12 mutated Ras (muRas) can be detected in the majority of patients with pancreatic cancer (3, 5). The proof of this T-cell response and the early presence of muRas in the tumoral process have prompted the implementation of clinical trials aimed at inducing CTL responses against defined muRas antigens (9–11). In these studies, immunizations with peptides of 13 to 17 amino acids in length were able to induce CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes specific for muRas. The latter were shown to be cytotoxic against autologous tumor cells or tumor cell lines (12–15).

However, the demonstration of these muRas-specific T cells required the expansion of the T cells *in vitro* by repeated stimulation with antigen and interleukin 2, which may result in quantitative and qualitative changes (5, 12–15), and the observed responses were not quantified (3). However, the recent development of accurate methods for assessment of T-cell responses, such as enzyme-linked immunospot (ELISPOT) or IFN- $\gamma$  fluorescence-activated cell sorting (FACS) analysis, allows for a more sensitive and more specific investigation of the naturally occurring T-cell response against tumor antigens (16, 17). The use of these methods should contribute to a better understanding of the occurrence and function of both CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses against muRas. Moreover, with respect to the development and application of therapeutic vaccine strategies using muRas as the target antigen, a method for immunomonitoring is warranted, which allows for the assessment of quantitative changes in muRas-specific T cells.

**Authors' Affiliations:** <sup>1</sup>Department of Internal Medicine I and <sup>2</sup>IV, <sup>3</sup>Department of Surgery, and <sup>4</sup>Institute of Pathology, University of Saarland Medical School, Homburg/Saar, Germany

Received 8/1/05; revised 11/13/05; accepted 12/5/05.

**Grant support:** Saarland University (HOMFOR) and Freunde der Universitätskliniken des Saarlandes e.V. (B. Kubuschok and M. Pfreundschuh).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Michael Pfreundschuh, Medizinische Klinik I, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar, Germany. Phone: 49-6841-162-3002; Fax: 49-6841-162-3101; E-mail: inmpr@uniklinikum-saarland.de.

© 2006 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-05-1672

Against this background, the objectives of this study were (a) to quantify and analyze the naturally occurring CD4<sup>+</sup>/CD8<sup>+</sup> T-cell response against muRas in HLA-A2 pancreatic carcinoma patients and healthy donors directly *ex vivo*; (b) to compare the magnitude and quality of the observed CD8<sup>+</sup> T-cell response against muRas peptides with the T-cell response against selected virus peptides; and (c) to establish a method adapted for immunomonitoring of muRas cancer vaccines.

## Materials and Methods

**Peripheral blood mononuclear cells and tissue from patients and healthy donors.** This study was approved by the local ethical review board ("Ethikkommission der Ärztekammer des Saarlandes") and done according to the Declaration of Helsinki. After informed consent, tumor tissue and peripheral blood mononuclear cells were obtained from 19 patients with histologically proven adenocarcinoma of the pancreas. Peripheral blood mononuclear cells were isolated by density gradient centrifugation using Ficoll-Paque Plus (Pharmacia Biotech, Freiburg, Germany). Pancreatico-duodenectomy (Whipple operation) or pancreatectomy was done at the University of Saarland Medical School (Homburg, Germany) between January 1997 and November 2000. All patients were typed HLA-A2 positive and their tumors were shown by PCR to bear one of the three most common *K-ras* mutations at amino acid position 12 (valine, aspartic acid, or arginine replacing glycine). Tumor stage and grading were determined according to the International Union against Cancer (UICC) classification (18). Peripheral blood mononuclear cell samples were also collected from HLA-A2-positive healthy donors who served as controls.

**Human leukocyte antigen typing.** HLA-A2 expression was shown using the antibody BB7.2 (immunoglobulin G2b; kindly provided by Dr. S. Stevanovic, Institute of Cell Biology, Tübingen, Germany). For indirect staining, dichlorotriazinylaminofluorescein-conjugated goat anti-mouse immunoglobulin G F(ab)<sub>2</sub> antibody (Dianova, Hamburg, Germany) was employed and samples were measured by FACScan (Becton Dickinson, Heidelberg, Germany).

**DNA extraction.** For *K-ras* mutation analysis DNA was extracted from formalin-fixed, paraffin-embedded tissue specimens using the QIAMP Tissue Kit (Qiagen, Hilden, Germany). Sections of 5 × 20 μm were transferred into a sterile 1.5-mL tube. Samples were taken from areas involved by the neoplasm as shown by staining of adjacent sections. Paraffin was removed by extracting twice with 1-mL xylene and twice with 1-mL absolute ethanol, followed by drying at 37°C for 10 minutes. The samples were digested with proteinase K at a concentration of 1.8 mg/mL at 55°C for 3 to 16 hours and loaded on a spin column afterwards. DNA was then absorbed by short centrifugation onto the QUIAMP silica membrane, washed twice, eluted with water, and stored at 4°C in Tris-EDTA buffer (19).

**PCR and sequencing.** Special precautions according to the standard operation procedures of the laboratory (available on request) were taken to avoid contamination, including separate handling of PCR reagents and products in different rooms and pipetting PCR reactions under a laminar air flow hood with filtered tips. Appropriate controls [PaTu cell line (mutation GGT to GTT at codon 12), Jurkat cell line (wild-type control at codon 12), and H<sub>2</sub>O for PCR contamination] were included in all reactions. Ten microliters of the proteinase-digested DNA from pancreatic carcinoma biopsies served as a template for PCR. PCR, enrichment PCR, and evaluation of their results were done as previously described (20, 21) based on the method of Kahn et al. (22) with minor modifications (20).

**Synthetic peptides.** The peptides were commercially synthesized (Neosystem, Strasbourg, France). The degree of purity was >95% by reverse-phase high-performance liquid chromatography and their identity was confirmed by mass spectrometric analysis. The peptide sequences derived from muRas are shown in Table 1. To evaluate the immune response against viruses, the following peptides were used: pp65<sub>495-503</sub> (NLVPMVATV) derived from cytomegalovirus (23),

influenza matrix protein (IMP<sub>58-66</sub>; GILGFVFTL) derived from the influenza virus (24), Pol<sub>476-484</sub> (ILKEPVHGV) derived from the human immunodeficiency virus (25), and LMP2<sub>426-434</sub> (CLGGLTMV; ref. 26) or BMLF-1<sub>280-288</sub> (GLCTLVAML; ref. 27) derived from Epstein-Barr virus.

**IFN-γ ELISPOT.** IFN-γ ELISPOT tests were done in 96-well multiscreen filtration plates (MAHAN 4550, Millipore, Bedford, MA) as described earlier (28). The number of spots was counted by a computer-assisted video image analyzer (Biosys, Karben, Germany). To determine the frequency of antigen-specific precursor-CTL in peripheral blood mononuclear cells of patients, a total of 2.4 × 10<sup>6</sup> peripheral blood mononuclear cells per patient were plated into 12 wells (i.e., 2 × 10<sup>5</sup> peripheral blood mononuclear cells per well) for each peptide of interest. Peripheral blood mononuclear cells simultaneously functioned as responder and stimulator cells in the respective well. The peptide of interest was added at 10 μg/mL of RPMI-AB supplemented with 100 units/mL interleukin 2. Frequencies of antigen-specific IFN-γ-secreting cells were calculated based on the number of spots per well after subtraction of the background (mean value from 12 wells). Background was obtained by culturing the responder cells with unloaded stimulator cells.

**Isolation of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes.** To obtain T-cell subpopulations for ELISPOT assays, peripheral blood mononuclear cells were treated with CD4 and CD8 antibody-coated magnetic microbeads (Dyna, Oslo, Norway), respectively, according to the recommendations of the manufacturer. Negative selection resulted in CD4<sup>+</sup> or CD8<sup>+</sup> cell suspensions with a purity of >95% as determined by FACS analysis. Negatively selected peripheral blood mononuclear cells (2 × 10<sup>5</sup>) were plated per well and a total of 2.4 × 10<sup>6</sup> negatively selected peripheral blood mononuclear cells per patient were plated into 12 wells for each peptide of interest.

**Intracellular FACS analysis.** Antigen stimulations with muRas, wild-type ras, or viral peptides were done in peripheral blood mononuclear cells essentially as described for cytomegalovirus-specific T cells (29). Briefly, 2 × 10<sup>6</sup> nonirradiated peripheral blood mononuclear cells were stimulated with 4 μg of the relevant peptide in the presence of 1 μg/mL anti-CD28 and 1 μg/mL anti-CD49d (clones L293 and L25.3; Becton Dickinson) and were immunostained with anti-CD4 or anti-CD8 (clones SK3 or SK1, peridinin chlorophyll protein; Becton Dickinson), anti-CD69 (clone L78, phycoerythrin; Becton Dickinson), and IFN-γ (clone 6402.3, fluorescein isothiocyanate; Becton Dickinson; ref. 29). At least 10,000 CD4<sup>+</sup> or CD8<sup>+</sup> lymphocytes were analyzed by FACScan (Becton Dickinson) and the percentage of specific T cells was calculated by subtraction of the frequency obtained by the respective control stimulations.

**In vitro generation of CTL.** CD4<sup>+</sup>-depleted peripheral blood mononuclear cells were plated at 2.5 × 10<sup>6</sup> per well in 24-well plates (Nunc, Wiesbaden, Germany) and were stimulated by autologous,

**Table 1.** Ras peptide sequences to detect T-cell responses against muRas epitopes

Type of Ras	Length (mer)	Sequence*
Ras wild-type (Gly12) 5-21	17	KLVVVGAGGVGKSALTI
Mutated Ras (Val12) 5-21	17	KLVVVGAVGVGKSALTI
Mutated Ras (Val12) 5-14	10	KLVVVGAVGV
Mutated Ras (Val12) 6-14	9	LVVVGAVGV
Mutated Ras (Asp12) 5-21	17	KLVVVGADGVGKSALTI
Mutated Ras (Asp12) 6-14	9	LVVVGADGV
Mutated Ras (Arg12) 5-21	17	KLVVVGARGVGKSALTI
Mutated Ras (Arg12) 6-14	9	LVVVGARGV

\* Bold-faced letters indicate mutated amino acids as compared with the wild-type sequence.

irradiated (30 Gy), muRas<sub>5-14</sub>-Val12 or muRas<sub>6-14</sub>-Val12 peptide-loaded peripheral blood mononuclear cells (stimulator cells; 2.5 × 10<sup>6</sup>) every week in the presence of 20 units/mL interleukin 2. Stimulator cells were incubated for 2 hours at 37°C in serum-free medium (X-VIVO 15, BioWhittaker Europe, Verviers, Belgium) with 10 µg/mL muRas<sub>5-14</sub>-Val12 or muRas<sub>6-14</sub>-Val12 peptide. After 4 weeks, resulting T-cell cultures were tested for their cytotoxic activity against different targets in varying effector/target ratios (1:5, 1:20, and 1:80): T2 cells (174 × CEM.T2 hybridoma, HLA-A2<sup>+</sup>, TAP1 and TAP2 deficient) not loaded or loaded (10 µg/mL) with muRas<sub>5-14</sub>-Val12 or muRas<sub>6-14</sub>-Val12 peptide (T2 muRas<sub>5-14</sub> or T2 muRas<sub>6-14</sub>) or control peptide (T2 HIV-pol). T2 cells without adding effector cells were used as another negative control. Reactivity of CTL lines was also tested against muRas-Val12-bearing pancreatic or colon cancer cell lines (Patu or SW480) positive or negative for HLA-A2 (S8988; kindly provided by B. Simon, Philipps University, Marburg, Germany). To block this reactivity, anti-HLA-A2 monoclonal antibody BB7.2 (kindly provided by S. Stevanovic, Institute of Cell Biology, Department of Immunology, Tuebingen, Germany) was added.

**Cytotoxicity assay.** As described earlier (28), T-cell cultures were tested for their specific cytotoxicity in a DNA fragmentation assay (30) with [<sup>3</sup>H]thymidine-labeled T2 cells or tumor cell lines as target cells. Each experiment was carried out at least in triplicate. Cytotoxicity was calculated as % specific killing = 100 - [(spontaneous retained DNA - experimental retained DNA) / spontaneous retained DNA] × 100. Spontaneous release was always <20% of the maximum release. For some target cells (tumor cell lines), standard chromium release assay was done alternatively (30). For this assay, 5 × 10<sup>5</sup> target cells were labeled with [<sup>51</sup>Cr]-sodium chromate for 1.5 hours at 37°C and washed thrice. [<sup>51</sup>Cr]-sodium chromate-labeled target cells (2 × 10<sup>4</sup>) were then added to varying numbers of effector cells in V-bottomed microwells. After incubation for 4 hours at 37°C, plates were centrifuged. Fifty microliters of supernatant per well were harvested and added to 200 µL scintillation solution OptiPhase "Supermix" in PET-G-plastic 96-well plates (Perkin-Elmer Wallac, Freiburg, Germany). After shaking the plates for 5 minutes, they were read with a scintillation gamma counter (1450 MicroBeta Trilux, Perkin-Elmer Wallac). Cytotoxicity was calculated as % specific killing = (experimental release - spontaneous lysis / maximum release - spontaneous release) × 100. Spontaneous release was always <10% of the maximum release.

**Statistical analysis.** SE values are presented as error bars in graphs. The comparison between precursor T-cell frequencies in patients and healthy donors was drawn by the Mann-Whitney *U* test. Cross tables were tested by  $\chi^2$  or Fisher's exact test where appropriate. Concerning the latter tests, a cutoff of six spots per well was applied to define a positive T-cell response in ELISPOT assays. Kaplan-Meier survival curves were calculated and the observed differences in survival were compared by log-rank test. *P* < 0.05 was considered significant.

**Results**

**Diversity of p21 ras mutations in pancreatic adenocarcinoma.** A prerequisite for an effective immune response against mutated p21 ras proteins in a cancer patient is the presence of the respective ras mutation in the tumor cells. Therefore, we identified 35 patients with *K-ras* codon 12 mutations in their primary tumor for further analysis of their immune response against muRas. Eighteen of 35 muRas-positive pancreatic adenocarcinomas showed amino acid substitution replacing glycine with valine (51%). Thirteen showed aspartic acid in amino acid position 12 (37%), three arginine in position 12 (9%), and one alanine in position 12 (3%). The determination of the HLA-A2 status, which is present in ~ 50% of the Caucasian population, was usually done before the analysis of ras mutations. Nineteen of 32 patients with muRas-positive pancreatic adenocarcinoma were shown to carry the HLA-A2 phenotype and were subjected

to analysis of T-cell response against HLA-A2-restricted peptides. In the remaining 13 cases, the HLA-A2 analysis was done retrospectively and was negative. No association was observed between the presence of the ras mutation in the tumor sample and the HLA-A2 phenotype of the individual.

**Study population.** The clinical characteristics of the 19 patients whose T-cell response was measured are given in Table 2. The median age was 61 years and the ratio of women to men was 1:1.37. Nine of 19 patients had stage III or VI of pancreatic cancer, 8 of 19 had stage II (=pT3N0M0), and only 2 had stage I disease according to the UICC classification (18). The primary tumor was resectable in 13 of 19 cases.

**Naturally occurring T-cell response against muRas<sub>5-21</sub> peptides.** To determine the naturally occurring T-cell response against mutated p21 ras oncoprotein, peripheral blood mononuclear cells were directly analyzed using IFN- $\gamma$  ELISPOT assay without prior *in vitro* stimulation. To detect circulating antigen-specific T cells, we induced IFN- $\gamma$  secretion by 17-mer muRas peptides containing the ras mutation present in the respective primary tumor of the patient. These 17-mer muRas<sub>5-21</sub> peptides comprised binding motifs for both MHC class I as well as MHC class II molecules (see Table 1) and were chosen based on peptide epitope prediction software SYFPEITHI (31). Following this approach, we found 6 of 19 patients (32%) mounting a specific T-cell response against muRas<sub>5-21</sub> peptides, with muRas-Val12 in four cases and muRas-Asp12 or muRas-Arg12 in one case, respectively. These patients showed 24 to 88

**Table 2. Patient characteristics and T-cell response against muRas<sub>5-21</sub>**

Characteristic	Number of patients per group	Number of patients with T-cell responses (%)
Age (y)	19	6 (32)
>60	11	5 (45)
≤60	8	1 (13)
Gender		
Male	11	5 (45)
Female	8	1 (13)
pT status		
pT <sub>2</sub>	2	0 (0)
pT <sub>3-4</sub>	17	6 (67)
pN status		
pN <sub>0</sub>	11*	4* (36)
pN <sub>1</sub>	6*	1* (17)
Stage		
I/II	10	3 (30)
III/IV	9	3 (33)
Resectability		
Resectable	13	4 (31)
Irresectable	6	2 (33)
Anatomic site		
Caput	13	2 (15) <sup>†</sup>
Corpus	6	4 (67)


\*n = 17 cases for pN.

†P = 0.046, caput versus corpus (Fisher's exact test).


spots per  $2 \times 10^5$  peripheral blood mononuclear cells in ELISPOT assay whereas the remaining patients showed 0 to 5 spots per  $2 \times 10^5$  peripheral blood mononuclear cells or well (Fig. 1). In contrast, in 19 healthy subjects, no more than four spots per well were detected, indicating a lack of a ras-specific immunity in these individuals (Fig. 1). The difference in the number of IFN- $\gamma$ -secreting T cells between healthy donors and patients with pancreatic cancer was statistically significant ( $P = 0.004$ , Mann-Whitney test). This was also true when a cutoff of six spots per well was used to define a positive T-cell response ( $P = 0.02$ , Fisher's exact test). No T-cell response specific for wild-type ras<sub>5-21</sub> was detected in any patient (zero to five spots per  $2 \times 10^5$  peripheral blood mononuclear cells; data not shown). Moreover, an assessment of IL-4 producing cells by ELISPOT did not reveal muRas-specific, IL-4-positive T lymphocytes in 8 healthy donors and 13 pancreatic cancer patients, including 3 with a muRas-specific, IFN- $\gamma$ -positive T-cell response (data not shown).

**Dissection of CD4 and CD8 T-cell responses against muRas<sub>5-21</sub> peptides.** In patients with a muRas<sub>5-21</sub>-specific T-cell response ( $n = 6$ ), we analyzed the fraction of CD4<sup>+</sup> and CD8<sup>+</sup> T-cell subpopulations by negative selection of peripheral blood mononuclear cells. This showed that the observed T-cell response included both CD8<sup>+</sup> and CD4<sup>+</sup> T cells; muRas-specific CD4<sup>+</sup> cells were found in a range of 12 to 182 per  $1 \times 10^5$  CD4<sup>+</sup> cells and muRas-specific CD8<sup>+</sup> cells were found in a range of 29 to 106 per  $1 \times 10^5$  CD8 cells (Fig. 2). In four of six patients, the T-cell response was dominated by CD8<sup>+</sup> cells (Fig. 2). As negative control, we isolated peripheral blood mononuclear cells of patients without a response to muRas<sub>5-21</sub>. Isolated CD4<sup>+</sup> or CD8<sup>+</sup> T cells of these patients did not result in positive ELISPOT assays ( $n = 3$ ). The results of a representative patient are shown in Fig. 2 (patient 7).

**Cross-reactivity of the immune response against muRas<sub>5-21</sub>.** In patients with response to muRas<sub>5-21</sub>, we analyzed the T-cell response against the ras mutation present in the primary tumor as well as the response against other frequent codon 12 mutations (muRas Val12, Asp12, and Arg12). In six of six



**Fig. 1.** Frequency of muRas<sub>5-21</sub>-specific T cells in patients with pancreatic adenocarcinoma and healthy donors. Peripheral blood mononuclear cells of 19 patients with pancreatic cancer and 19 healthy donors were tested against muRas<sub>5-21</sub> peptide. Given is the number of spots per well corresponding to the number of IFN- $\gamma$ -secreting T cells per 200,000 peripheral blood mononuclear cells. Points, median number of 12 tested wells.



**Fig. 2.** Proportion of CD4<sup>+</sup>/CD8<sup>+</sup>-muRas 5-21-specific T cells in patients with pancreatic adenocarcinoma. The ratio of CD4<sup>+</sup>/CD8<sup>+</sup> T-cell subpopulations in response against muRas<sub>5-21</sub> was measured in patients with pancreatic cancer. CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes were negatively selected by magnetic beads and subjected to IFN- $\gamma$  ELISPOT assay. Peripheral blood mononuclear cells were stimulated with peptides corresponding to the ras codon 12 mutation of their primary tumor (Val12, Asp12, and Arg12). Given is the number of spots per well (median of 12 wells) corresponding to the number of IFN- $\gamma$  secreting T cells per 100,000 CD4<sup>+</sup> or CD8<sup>+</sup> T lymphocytes. Bars, SD.

patients, the detected CD8<sup>+</sup> and CD4<sup>+</sup> T lymphocytes were specific for the mutation expressed by the primary tumor and the T-cell response against this mutation did not cross-react with other ras mutations or wild-type ras (data not shown).

**CD8<sup>+</sup> T-cell response against muRas<sub>5-14</sub> and muRas<sub>6-14</sub>.** To determine which epitope elicits the CD8<sup>+</sup> T-cell response against muRas-Val12, we used the HLA-A2 class I-restricted peptides muRas<sub>5-14</sub>-Val12 and muRas<sub>6-14</sub>-Val12 for stimulation in ELISPOT assays. These epitopes had been predicted to display a high binding capacity to HLA-A\*0201 by SYFPEITHI. In all patients who showed a T-cell response to muRas<sub>5-21</sub>-Val12 ( $n = 4$ ), we also observed a strong CD8<sup>+</sup> T-cell response against muRas<sub>6-14</sub> (10-23 spots per  $2 \times 10^5$  peripheral blood mononuclear cells). Similarly, CD8<sup>+</sup> T-cell responses were detected against muRas<sub>5-14</sub>-Val12 in three of four patients (17-23 spots per  $2 \times 10^5$  peripheral blood mononuclear cells). It is noteworthy that the magnitude of the T-cell response against the examined muRas-Val12 peptides was different: the 17-mer peptide elicited IFN- $\gamma$  secretion in a larger proportion of T cells in comparison with the shorter 9- and 10-mer peptides (Fig. 3), suggesting a combined stimulation of IFN- $\gamma$  secretion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells by the 17-mer, with the short peptides exclusively activating CD8<sup>+</sup> T cells.

In a proportion of patients with pancreatic carcinoma, we analyzed the frequency of a muRas-specific CD8<sup>+</sup> T-cell response against nonamer peptides. MuRas<sub>6-14</sub>-specific CD8<sup>+</sup> cells were found in 6 of 13 patients (data not shown). Similarly, muRas<sub>5-14</sub> specific CD8<sup>+</sup> cells were found in four of nine patients. In contrast, muRas<sub>6-14</sub>- or muRas<sub>5-14</sub>-specific T-cell responses were not observed in healthy donors ( $P = 0.015$  and  $P = 0.026$ , respectively, Fisher's exact test). In one patient, muRas-specific T cells could only be detected with short peptides (9- and 10-mer) but not with the 17-mer peptide (data not shown).


The CD8<sup>+</sup> T-cell response against muRas<sub>6-14</sub> or muRas<sub>5-14</sub> was not only investigated by ELISPOT but also in parallel by IFN- $\gamma$  FACS analysis. In all patients ( $n = 6$ ) with a CD8<sup>+</sup> response as shown by ELISPOT, we could confirm the presence of IFN- $\gamma$ -secreting CD8<sup>+</sup> T cells, with frequencies ranging

Downloaded from http://aacrjournals.org/clinccancerres/article-pdf/12/4/1365/1967367/1365.pdf by guest on 08 February 2023

between 0.05% and 0.1% of all CD8<sup>+</sup> T cells (test value minus negative control). A representative example of a CD8<sup>+</sup> T-cell response against muRas<sub>6-12</sub> is shown in Fig. 4.

**Function of muRas<sub>5-14</sub>- and muRas<sub>6-14</sub>-specific CD8<sup>+</sup> T cells.** To evaluate the function of muRas<sub>6-14</sub>- and muRas<sub>5-14</sub>-specific CD8<sup>+</sup> T cells, we tested the cytotoxic activity of these T cells after weekly stimulation with muRas-loaded peripheral blood mononuclear cells over a period of 4 weeks. CD8<sup>+</sup> T cells stimulated in this way killed muRas<sub>6-14</sub>- and muRas<sub>5-14</sub>-loaded T2 cells but not empty T2 cells or T2 cells loaded with control peptide (HIV-pol; Fig. 5A and B). They also showed cytotoxic activity against HLA-A2-positive, muRas-Val12-bearing pancreatic or colon cancer cell lines (PaTu and SW480) but not against a HLA-A2-negative, muRas-Val12-bearing pancreatic carcinoma cell line (S8988; Fig. 6A and B). The cytotoxic activity could be blocked by anti-HLA class I antibodies (Fig. 6A and B). These results indicate that muRas-specific CTLs can be generated from naturally occurring muRas<sub>6-14</sub>- and muRas<sub>5-14</sub>-specific T cells. In addition, they confirm the natural processing of muRas<sub>6-14</sub> and muRas<sub>5-14</sub> in pancreatic cancer cells.

**Magnitude of muRas<sub>6-14</sub>-specific CD8 T cells in comparison with virus-specific CD8 T-cell response.** In addition to the CD8<sup>+</sup>



**Fig. 4.** Frequency of CD8 T-cell response against muRas-Val12 peptide 6-14. Representative example of CD8 T-cell response against muRas 6-12 in a patient with pancreatic cancer as measured by FACS analysis. Peripheral blood mononuclear cells (200,000) were incubated with nonamer 6-14 or without peptide (negative control). Bottom right quadrant, numbers indicate percentage of stimulated CD8 T cells. Frequency of muRas-specific cells is calculated as test value minus negative control (0.13-0.07% = 0.06%). Please note the stronger mean fluorescence intensity of IFN- $\gamma$  in muRas peptide-stimulated T cells in comparison to negative control. X axis, IFN- $\gamma$ . Y axis, CD69.


response against muRas-Val12 peptide epitopes, we examined the magnitude of the CD8<sup>+</sup> response against HLA-A2-restricted viral peptide epitopes (IMP, EBV antigens LMP2 and BMLF1) by ELISPOT: the response against viral peptides revealed a heterogeneous picture with higher, similar or lower frequency of virus-specific CD8<sup>+</sup> T cells depending on the respective viral peptide in comparison with the frequency of muRas<sub>6-14</sub>-specific CD8<sup>+</sup> T cells (Fig. 3B). These results were confirmed by IFN- $\gamma$  FACS analysis (data not shown).

**Naturally occurring T-cell response against viral peptides.** A comparison of the CD8<sup>+</sup> response against HLA-A2-restricted viral peptide epitopes (IMP, EBV antigens LMP2 and BMLF1 and cytomegalovirus-antigen pp65) did not reveal differences in the occurrence of virus-specific T cells between patients with pancreatic carcinoma and healthy donors ( $n = 14$ ; data not shown).


**T-cell response against muRas and correlation with clinical and prognostic variables.** T-cell responses against muRas were not correlated with clinical or prognostic variables such as tumor-node-metastasis status, stage, grading, or resectability of the primary tumor (Table 2). There was also no association with age, gender, or the concentration of CA 19-9 in their serum. Patients were followed for survival with a median observation time of 4.8 years. There was no statistically significant difference of the survival curves between muRas responders and non-responders. It is noteworthy, however, that differences between groups might not have been discovered because of the limited number of patients. Surprisingly, a T-cell response against muRas was more frequently found if the primary tumor was localized in the cauda or corpus of the pancreas and not in the caput (Table 2, last row;  $P = 0.046$ , Fisher's exact test).

## Discussion

In this study, we provide evidence for a naturally occurring CD8<sup>+</sup> and CD4<sup>+</sup> T-cell response against muRas proteins in the circulating T lymphocyte pool of a considerable proportion of HLA-A2-positive pancreatic cancer patients (32%). In contrast to previous studies in muRas-bearing cancer patients, we analyzed the T-cell response and quantified its magnitude without prior



**Fig. 3.** A, comparison of T-cell response against muRas-Val12 peptides of different lengths. Peripheral blood mononuclear cells (PBMC) of pancreatic carcinoma patients ( $n = 4$ ) were stimulated with nonamer 6-14, decamer 5-14, and heptadecamer 5-21 peptides derived from muRas. B, comparison of muRas-specific with virus-specific CD8 T-cell response. Peripheral blood mononuclear cells of pancreatic carcinoma patients ( $n = 5$ ) were stimulated with nonamer peptides derived from mutated Ras (muRas<sub>6-14</sub>) and different virus proteins: IMP (58-66) from influenza-virus and LMP-2 (426-434) or BMLF-1 (280-88) from Epstein-Barr virus. Columns, number of spots per well (median of 12 wells) corresponding to the number of IFN- $\gamma$ -secreting T cells per 200,000 peripheral blood mononuclear cells. Bars, SD.




**Fig. 5.** Cytotoxicity of muRas-Val12 peptide 5-14 (A) or 6-14 (B) stimulated CD8 T cells against peptide loaded targets. MuRas<sub>5-14</sub>- and muRas<sub>6-14</sub>-specific CD8<sup>+</sup> cells kill muRas<sub>5-14</sub>- and muRas<sub>6-14</sub>-loaded T2 cells (black columns) but not empty T2 cells (dark gray columns) or T2 cells loaded with control peptide (HIV-pol; left light gray columns). Columns, percent specific killing representative for T-cell bulk cultures of three (A) or two patients (B) with pancreatic cancer; bars, SD. T2 cells without adding effector cells were used as another negative control (right light gray columns).

*in vitro* stimulation. The observed T cells can be considered as naturally occurring because the IFN- $\gamma$  ELISPOT which was used for their assessment detects only antigen-experienced T cells. The investigation of T-cell subgroups revealed that the T-cell response against muRas involved both CD8<sup>+</sup> and CD4<sup>+</sup> T lymphocytes. Interestingly, in the majority of patients, the CD8<sup>+</sup> T-cell response was predominant in comparison with the CD4<sup>+</sup> T-cell response. This has not been shown in previous studies in which muRas-specific cytotoxic CD8<sup>+</sup> T lymphocytes were only detected after several rounds of *in vitro* stimulation, even in patients vaccinated with muRas 13- to 17-mer peptides (12, 15, 32). This may be explained by the low sensitivity of the assays to detect a CD8<sup>+</sup> T-cell response (e.g., limited dilution assay) used in those studies (9, 11) or simply because CD8<sup>+</sup> T-cell response was missed due to the fact that the relevant MHC class I-restricted peptides were unknown (3, 5). In contrast, CD4<sup>+</sup> T-cell responses have been shown in 44% to 75% of patients with pancreatic cancer (3, 15). Because muRas is an intracellular protein, it is susceptible to the endogenous pathway of antigen processing and loading on MHC class I molecules. Mechanisms related to malignancy such as tumor necrosis might enable access of the sequestered protein to the MHC class II pathway of antigen-

presenting cells. Analogous observations have been reported from other cancer-related intracellular proteins such as p53 (33).

Notably, CD8<sup>+</sup> as well as CD4<sup>+</sup> T-cell responses corresponded to the ras mutation expressed by the primary tumor of a patient and the T-cell response against this mutation did not cross-react with other ras mutations or wild-type ras. To determine the HLA-A2-restricted CD8<sup>+</sup> response in more detail, a nonamer and a decamer peptide predicted by peptide prediction software SYFPEITHI (31) to bind to HLA-A2 were tested for their capacity to detect antigen-experienced T-cell responses. The peptides 5-14 and 6-14 derived from muRas-Val12 elicited CD8<sup>+</sup> T-cell responses which could be detected by IFN- $\gamma$  ELISPOT and confirmed by IFN- $\gamma$ -FACS analysis. We also showed that these peptides are targets of CTLs generated from muRas<sub>5-14</sub>- and muRas<sub>6-14</sub>-loaded antigen-presenting cells and that these CTLs are able to kill HLA-A2-positive, muRas-Val12-bearing pancreatic cancer cells. The latter fact shows that these peptides are naturally processed in pancreatic cancer. Data from another group support the immunogenicity of the muRas<sub>5-14</sub> peptide.



**Fig. 6.** Cytotoxicity of muRas-Val12 peptide 5-14 (A) or 6-14 (B) stimulated CD8 T cells against pancreatic carcinoma cell lines. MuRas<sub>5-14</sub>- and muRas<sub>6-14</sub>-specific CD8<sup>+</sup> cells killed muRas-Val12-bearing, HLA-A2-positive pancreatic cells (PaTu; black column) but not HLA-A2-negative, muRas-Val12-bearing pancreatic cancer cells (S8988; right light gray columns). Cytotoxicity could be blocked by an anti-HLA class I antibody (left light gray columns). MuRas-Val12-bearing, HLA-A2-positive colon cancer cells are also killed (SW480; dark gray columns). Columns, percent specific killing representative for T-cell bulk cultures of three (A) or two patients (B) with pancreatic cancer; bars, SD.

These investigators established a cytotoxic CD8<sup>+</sup> T-cell line against muRas<sub>5-14</sub>-Asp12 in a patient with colon carcinoma (15).

In pancreatic cancer patients, we detected 5 to 12 CD8<sup>+</sup> T cells per 100,000 peripheral blood mononuclear cells in an ELISPOT assay using muRas<sub>5-14</sub> or muRas<sub>6-14</sub>. This frequency is ~1 log beyond the detection limit of IFN- $\gamma$  ELISPOT (1/100,000 peripheral blood mononuclear cells). In other tumor entities like colorectal carcinoma or melanoma, the frequencies of CD8<sup>+</sup> T cells specific for the relevant tumor antigens are in the same range (5, 34–36). For example, Nagorsen et al. (34) showed 3 to 20 Ep-CAM-specific CD8<sup>+</sup> T cells and 1 to 8 Her-2/neu-specific CD8<sup>+</sup> T cells per 100,000 peripheral blood mononuclear cells in colorectal cancer. However, it must be kept in mind that the ELISPOT assays done in different laboratories are not standardized, making a comparison of the number of the observed spots difficult. Therefore, attempts have been made to standardize this technique and to evaluate the reliability of the T-cell frequency analysis. Consistent frequencies of model viral peptide-specific T cells were observed by ELISPOT assay in different laboratories (36).

In this study, we did not find correlations between a specific immune response against muRas and tumor-node-metastasis status, stage, or serum levels of CA-19-9. This does not support the hypothesis that a high tumor load leads to a strong T-cell response (34) or the opposite hypothesis that a high tumor load is associated with immunosuppression. Although data from selected patients suggest a favorable clinical course in patients with naturally occurring T-cell response in peripheral

blood mononuclear cells (37, 38) or intratumorally (12, 39), no study has systematically investigated the prognostic significance of tumor antigen-specific T lymphocytes in peripheral blood mononuclear cells. Because of the limited number of patients with detectable muRas T-cell response, we could also not consider this question in a sufficient way. The observation that pancreatic adenocarcinomas located in the cauda or corpus elicit an immune response more frequently than adenocarcinomas located in the caput is difficult to interpret. Whether this is related to the anatomic characteristics of the pancreatic lymphatics (40) remains open for speculation.

To summarize, we have shown a T-cell response against muRas proteins in a significant proportion of patients with pancreatic carcinoma. The ELISPOT assay using the described muRas derived peptides is a useful tool for immunologic monitoring of muRas cancer vaccine trials because it is more informative than the qualitative tests described thus far. The goal of a vaccination with muRas is to boost the preexistent immune response and/or to overcome their possible functional deficits. To this end, we recently developed a novel cancer vaccine using genetically modified lymphoblastoid cell lines (28) which elicits a strong muRas-specific T-cell response *in vitro*. A clinical pilot study to evaluate this approach is ongoing.

## Acknowledgments

We thank A. Bulle-Sek for excellent technical assistance.

## References

- Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. *Semin Oncol* 1996;23:118–34.
- Takahashi M, Chen W, Byrd DR, et al. Antibody to ras proteins in patients with colon cancer. *Clin Cancer Res* 1995;1:1071–7.
- Qin H, Chen W, Takahashi M, et al. CD4<sup>+</sup> T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. *Cancer Res* 1995;55:2984–7.
- Linard B, Bezieau S, Benlalam H, et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. *J Immunol* 2002;168:4802–8.
- Shono Y, Tanimura H, Iwahashi M, et al. Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers. *Br J Cancer* 2003;88:530–6.
- Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. *J Exp Med* 1991;173:273–6.
- Van Elsland A, Nijman HW, Van der Minne CE, et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A\*0201. *Int J Cancer* 1995;61:389–96.
- Bergmann-Leitner ES, Kantor JA, Shupert WL, Schlom J, Abrams SI. Identification of a human CD8<sup>+</sup> T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. *Cell Immunol* 1998;187:103–16.
- Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. *Int J Cancer* 2001;92:441–50.
- Carbone DP, Ciernik IF, Kelley MJ, et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. *J Clin Oncol* 2005;23:5099–107.
- Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. *J Immunother* 1999;22:155–65.
- Naito Y, Saito K, Shiiba K, et al. CD8<sup>+</sup> T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Res* 1998;58:3491–4.
- Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. *Int J Cancer* 1997;72:784–90.
- Gjertsen MK, Saeterdal I, Saebøe-Larssen S, Gaudernack G. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. *J Mol Med* 2003;81:43–50.
- Abrams SI, Khleif SN, Bergmann-Leitner ES, et al. Generation of stable CD4<sup>+</sup> and CD8<sup>+</sup> T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. *Cell Immunol* 1997;182:137–51.
- Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. *Cancer Immunol Immunother* 2004;53:249–55.
- Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ. Design and evaluation of antigen-specific vaccination strategies against cancer. *Curr Opin Immunol* 2000;12:576–82.
- Balzano G, Bassi C, Zerbi A, et al. Evaluation of UICC TNM classification for pancreatic cancer. A study of 228 patients. *Int J Pancreatol* 1997;21:111–8.
- Merkelbach S, Gehlen J, Handt S, Fuzesi L. Novel enzyme immunoassay and optimized DNA extraction for the detection of polymerase-chain-reaction-amplified viral DNA from paraffin-embedded tissue. *Am J Pathol* 1997;150:1537–46.
- Jacobs G, Tscholl E, Sek A, Pfreundschuh M, Daus H, Trumper L. Enrichment polymerase chain reaction for the detection of Ki-ras mutations: relevance of Taq polymerase error rate, initial DNA copy number, and reaction conditions on the emergence of false-positive mutant bands. *J Cancer Res Clin Oncol* 1999;125:395–401.
- Trumper L, Menges M, Daus H, et al. Low sensitivity of the ki-ras polymerase chain reaction for diagnosing pancreatic cancer from pancreatic juice and bile: a multicenter prospective trial. *J Clin Oncol* 2002;20:4331–7.
- Kahn SM, Jiang W, Culbertson TA, et al. Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. *Oncogene* 1991;6:1079–83.
- Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. *J Virol* 1996;70:7569–79.
- Bednarek MA, Sauma SY, Gammon MC, et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. *J Immunol* 1991;147:4047–53.
- Goulder PJ, Sewell AK, Lalloo DG, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A\*0201 are influenced by epitope mutation. *J Exp Med* 1997;185:1423–33.
- Lee SP, Thomas WA, Murray RJ, et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. *J Virol* 1993;67:7428–35.
- Steven NM, Annels NE, Kumar A, Leese AM,

- Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. *J Exp Med* 1997;185:1605–17.
28. Kubuschok B, Schmits R, Hartmann F, et al. Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. *Hum Gene Ther* 2002;13:815–27.
29. Sester M, Sester U, Gartner B, et al. Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. *J Virol* 2002;76:3748–55.
30. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. *J Immunol Methods* 1991;145:185–92.
31. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics* 1999;50:213–9.
32. Fossum B, Olsen AC, Thorsby E, Gaudernack G. CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation. *Cancer Immunol Immunother* 1995;40:165–72.
33. Fujita H, Senju S, Yokomizo H, et al. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. *Eur J Immunol* 1998;28:305–16.
34. Nagorsen D, Keilholz U, Rivoltini L, et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. *Cancer Res* 2000;60:4850–4.
35. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipptide vaccine in patients with melanoma. *Clin Cancer Res* 2003;9:641–9.
36. Scheibenbogen C, Romero P, Rivoltini L, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFN- $\gamma$ -ELISPOT assay and chromium-release assay: a four-centre comparative trial. *J Immunol Methods* 2000;244:81–9.
37. Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting *ex vivo* tumor-specific cytolytic activity. *Cancer Res* 2002;62:1743–50.
38. Karanikas V, Colau D, Baurain JF, et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. *Cancer Res* 2001;61:3718–24.
39. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. *N Engl J Med* 2003;348:203–13.
40. Ungeheuer A, Liebermann-Meffert D. [An anatomic study of the pancreatic lymphatics. Review of the summary and an abridged version of the original text]. *Langenbecks Arch Chir* 1990;375:303–7.